Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 6 art units • 10 examiners • 0 of 14 (0%) have an AI response strategy ready
Remix Therapeutics Inc. has 14 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 10 distinct examiners across 6 distinct art units, creating a dispersed prosecution profile that requires both portfolio coordination and matter-level analysis.
VISHNYAKOVA, ELENA VLADIMIROVNA is the busiest examiner, with 4 pending matters. This allocation gives that examiner a larger share of the pending work than the other identified examiners, making examiner-specific review particularly relevant.
The art-unit spread indicates that the portfolio is not confined to a single technical examination setting. Counsel can organize responses by art unit while also monitoring the examiner with the largest pending allocation.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (7%) |
| §112 only | 2 (14%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 4 (29%) |
| Multi-statute (no §101) | 5 (36%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VISHNYAKOVA, ELENA VLADIMIROVNA | 4 | 68.3% | +46.6% |
| NESTOR, DONNA MICHELLE | 2 | 56.6% | +44.2% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| ROMERO, KRISTEN WANG | 1 | 69.8% | +30.8% |
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
| CHICKS, ASHLI ARIANA | 1 | 60.0% | +51.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18726007 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NESTOR, DONNA MICHELLE | — |
| 18688087 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | ROMERO, KRISTEN WANG | — |
| 18688088 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| 18688100 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| 17802833 | FUSED BICYCLIC COMPOUNDS USEFUL FOR MODULATING NUCLEIC ACID SPLICING | CHICKS, ASHLI ARIANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014059 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE | MCDOWELL, BRIAN E | 87d overdue |
| 17917729 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | NESTOR, DONNA MICHELLE | 23d overdue |
| 18014057 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MOORE, SUSANNA | 78d |
| 18726007 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NESTOR, DONNA MICHELLE | — |
| 18713561 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | WHITE, DAWANNA SHAR-DAY | — |
| 18688098 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| 18688087 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | ROMERO, KRISTEN WANG | — |
| 18688088 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| Art Unit | Apps |
|---|---|
| 1691 | 5 |
| 1624 | 3 |
| 1627 | 2 |
| 1621 | 1 |
| 1625 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18726007 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NESTOR, DONNA MICHELLE | — | §102§112Other | Non-Final OA | — | Pending | Jul 01, 2024 |
| 18713561 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | WHITE, DAWANNA SHAR-DAY | 1627 | §102§103§112DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18688098 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103§112DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18688087 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | ROMERO, KRISTEN WANG | 1624 | §102§112Other | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18688088 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103§112Other | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18688100 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103§112 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18688081 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | SHIAO, REI TSANG | 1691 | DP | Final Rejection | — | Pending | Feb 29, 2024 |
| 18014057 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MOORE, SUSANNA | 1624 | §112Other | Non-Final OA | 78d | Pending | Dec 30, 2022 |
| 18014059 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE | MCDOWELL, BRIAN E | 1624 | §112 | Final Rejection | 87d overdue | Pending | Dec 30, 2022 |
| 17917868 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | NOTTINGHAM, KYLE GREGORY | 1621 | §112DP | Non-Final OA | — | Pending | Oct 07, 2022 |
| 17917729 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | NESTOR, DONNA MICHELLE | 1627 | Other | Non-Final OA | 23d overdue | Pending | Oct 07, 2022 |
| 17802702 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | MAHLUM, JONATHAN DAVIS | 1625 | §112DP | Final Rejection | — | Pending | Aug 26, 2022 |
| 17802833 | FUSED BICYCLIC COMPOUNDS USEFUL FOR MODULATING NUCLEIC ACID SPLICING | CHICKS, ASHLI ARIANA | 1626 | §102§103 | Non-Final OA | — | Pending | Aug 26, 2022 |
| 17802747 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103Other | Non-Final OA | — | Pending | Aug 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRemix Therapeutics Inc. has 14 pending office actions as of October 2026, spread across 6 art units and 10 examiners.
Elena Vladimirovna Vishnyakova has the most, with 4 of Remix Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
